{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:42Z","timestamp":1791333402487,"version":"4.3.1"},"reference-count":73,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T00:00:00Z","timestamp":1117670400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy of anakinra treatment in patients with adult\u2010onset Still's disease (AOSD) that is refractory to corticosteroids, methotrexate (MTX), and etanercept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four patients with AOSD were treated with prednisone and MTX and 2 patients were also treated with etanercept for worsening symptoms and indicators of systemic inflammation. White blood cells (WBCs), C\u2010reactive protein (CRP) levels and\/or erythrocyte sedimentation rate, and ferritin levels were measured and, in 1 patient, serum creatinine levels were determined. Treatment with anakinra at 100 mg\/day was initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The index patient's disease was refractory to treatment with prednisone (30 mg\/day) and MTX, with spiking fevers, rash, synovitis, a serum ferritin level of 8,400 ng\/ml (normal \u2264200), and a CRP level of 86 mg\/liter (normal &lt;8). Levels of interleukin\u20101\u03b2 (IL\u20101\u03b2), IL\u20101\u03b1, IL\u20106, IL\u20101 receptor antagonist, and IL\u201018 were elevated. Just prior to anakinra treatment, the WBC count was 14,600\/mm<jats:sup>3<\/jats:sup>, the CRP level was 86 mg\/liter, and the ferritin level was 573 ng\/ml, with daily spiking fevers to 104\u00b0F, rash, and swollen joints. Within hours of the first injection, the patient was afebrile and asymptomatic; within days, the WBC count, ferritin level, and CRP level decreased into the normal range. On 2 occasions, anakinra was withheld. Within a few days, the WBC count rose to &gt;20,000\/mm<jats:sup>3<\/jats:sup>with prominent neutrophilia, the CRP level rose to &gt;200 mg\/liter, and the ferritin level rose to &gt;3,000 ng\/ml. Upon restarting anakinra, the patient became afebrile, the WBC count fell to 8,000\/mm<jats:sup>3<\/jats:sup>, the CRP level fell to &lt;3 mg\/liter, and the ferritin level fell to &lt;300 ng\/ml. Three additional patients with refractory AOSD who experienced rapid reductions in fever, symptoms, and markers of inflammation when treated with anakinra are reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Refractory AOSD appears to be IL\u20101\u2013mediated since anakinra decreases hematologic, biochemical, and cytokine markers and also produces rapid reductions in systemic and local inflammation. Reported efficacy of tumor necrosis factor\u2013blocking therapies in AOSD may be due to a reduction in IL\u20101.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21061","type":"journal-article","created":{"date-parts":[[2005,6,3]],"date-time":"2005-06-03T13:03:52Z","timestamp":1117803832000},"page":"1794-1803","source":"Crossref","is-referenced-by-count":296,"title":["Rapid responses to anakinra in patients with refractory adult\u2010onset Still's disease"],"prefix":"10.1002","volume":"52","author":[{"given":"Avril A.","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"LeClercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Homik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197309000-00007"},{"key":"e_1_2_6_3_2","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi M","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel B","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199103000-00004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097498442307"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01238-X"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939309010646"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490240060037"},{"key":"e_1_2_6_10_2","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still's disease","volume":"30","author":"Choi JH","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_2","first-page":"113","article-title":"A case of adult onset Still's disease treated with infliximab","volume":"20","author":"Caramaschi P","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-003-0744-z"},{"issue":"3","key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60","author":"Kraetsch HG","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_14_2","first-page":"414","article-title":"Inhibition of the TNF\u2010pathway: use of infliximab and etanercept as remission\u2010inducing agents in cases of therapy\u2010resistant chronic inflammatory disorders","volume":"132","author":"Aeberli D","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-003-0775-5"},{"key":"e_1_2_6_16_2","first-page":"329","article-title":"Infliximab in the treatment of adult Still's disease refractory to conventional therapy","volume":"19","author":"Cavagna L","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.041611398"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308705101"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2001.0914"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(03)00091-0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20268"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.30.2.121"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198403000-00002"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10231"},{"issue":"9","key":"e_1_2_6_25_2","first-page":"S229","article-title":"Etanercept in recalcitrant adult onset Still's disease (AOSD)","volume":"43","author":"Tamesis ER","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_26_2","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel M","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"e_1_2_6_27_2","first-page":"263","article-title":"Anakinra in the treatment of adult onset Still's disease","volume":"63","author":"Haraoui B","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_6_28_2","first-page":"265","article-title":"Prompt response to treatment with anakinra in adult onset Still's disease","volume":"63","author":"Aelion JA","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11151"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.6.1433"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.5.1627"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.02.039"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.8.1328"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199110000-00010"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911015)68:8<1694::AID-CNCR2820680806>3.0.CO;2-K"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4049\/jimmunol.156.1.389","article-title":"IL\u20101\u03b2 does not cause neutrophil degranulation but does lead to IL\u2010 6, IL\u20108, and nitrite\/nitrate release when used in patients with cancer","volume":"156","author":"Ogilvie AC","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303183281103"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1141"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood.V78.6.1420.1420","article-title":"A phase I trial of recombinant human interleukin\u20101\u03b2 alone and in combination with myelosuppressive doses of 5\u2010fluorouracil in patients with gastrointestinal cancer","volume":"78","author":"Crown J","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309145750"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01696346"},{"key":"e_1_2_6_43_2","first-page":"583","article-title":"Phase I study of recombinant human interleukin\u20101\u03b2 (rhIL\u20101\u03b2) in patients with bone marrow failure","volume":"14","author":"Nemunaitis J","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.10.004"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4666(03)00152-2"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02918142"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095"},{"key":"e_1_2_6_48_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V79.3.693.693","article-title":"Effects on leukocytes after injection of tumor necrosis factor into healthy humans","volume":"79","author":"Van der Poll T","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.344"},{"key":"e_1_2_6_50_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/10428199709039044","article-title":"A phase I study of interleukin\u20106 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease","volume":"25","author":"Imrie KR","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_6_51_2","first-page":"935","article-title":"Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer","volume":"15","author":"Lazarus HM","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_52_2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute\u2010phase proteins following anti\u2010TNF\u2010\u03b1 therapy in rheumatoid arthritis","volume":"163","author":"Charles P","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199401000-00008"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06368.x"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.4.1243"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90154-X"},{"key":"e_1_2_6_57_2","first-page":"R400","article-title":"Physiological and cytokine responses in interleukin\u20101\u03b2\u2010deficient mice after zymosan\u2010induced inflammation","volume":"273","author":"Fantuzzi G","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb08310.x"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.311"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.08.033"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng756"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17401-1"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(04)00046-9"},{"issue":"9","key":"e_1_2_6_64_2","first-page":"S517","article-title":"Treatment of neonatal onset multisystem inflammatory disease (NOMID) with IL\u20101Ra (anakinra)","volume":"48","author":"Lovell DJ","year":"2003","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306193482523"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20033"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10688"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10620"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363922"},{"key":"e_1_2_6_71_2","unstructured":"SiegelJ. FDA briefing document on safety and efficacy update on approved TNF\u2010blocking agents. URL:www.FDA.gov\/ohrms\/dockets\/ac\/03."},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10870"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21061","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T14:24:11Z","timestamp":1735741451000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1002\/art.21061"],"URL":"https:\/\/doi.org\/10.1002\/art.21061","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}